IIT Assessing OC-01Nasal Spray on Symptoms of DED Following CXL

Phase 2 Unknown 20 enrolled Vance Thompson Vision - MT

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Controlled, Double-Masked, Two-Arm Investigator-Initiated study to Assess the Efficacy of OC-01 (varenicline) Nasal Spray on signs and symptoms of Dry Eye Disease in subjects following Corneal Collagen Crosslinking (CXL)

Timeline

Start: 2021-12-01
Primary completion: 2022-06-01
Completion: 2022-06-01

Outcome

Missed primary endpoint

paper the difference was not statistically significant at any time point. PMID 40088395 ↗

Publications

Ferguson TJ, Durgan D, Whitt T, Swan RJ. Varenicline Nasal Spray for the Treatment of Dry Eye Disease Following Corneal Collagen Crosslinking. Ophthalmol Ther. 2025 May;14(5):959-968. doi: 10.1007/s40123-025-01118-x. Epub 2025 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OC-01	Small molecule	0.03 mg	Intranasal
Subject	OC-01	Small molecule	1.2 mg/ml	Intranasal